retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity First 3 data, a Triumph of Science! Obesity drug research, triple G
Description
doi: 10.1038/ijo.2011.158 [DOI] [PMC free article] [PubMed] [Google Scholar] 240
Toxicon 60 , 319 (2012)
[DOI] [PubMed] [Google Scholar] 149.Wu X.F., Wu X.X., Guo W.J., Luo Q., Gu Y.H., Shen Y., Tan R.X., Sun Y., Xu Q., Cerebroside D., et al
Patients report forgetting to eat, feeling full after a few bites, and losing interest in food entirely
This efficiency reflects the designers understanding that the triple receptor profile provides robust efficacy even at the earlier dose levels, allowing for a more streamlined escalation
